Close Menu

NEW YORK – Biotech company Adarza BioSystems said on Tuesday that it has raised $25 million in a Series D financing round.

The round was co-led by 3x5 Partners and Lightchain Capital. With the closing of the Series D round, Adarza also added Lightchain Managing Director Drew Dennison and 3x5 Partners Managing Director Joe Biller to its board.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.